Imaging robust microglial activation after lipopolysaccharide administration in humans with PET

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 40, 2015, Pages 12468-12473

  Sandiego, Christine M ^a,b   Gallezot, Jean Dominique ^b   Pittman, Brian ^a   Nabulsi, Nabeel ^b   Lim, Keunpoong ^b   Lin, Shu Fei ^b   Matuskey, David ^a,b   Lee, Jae Yun ^a   O'Connor, Kevin C ^a   Huang, Yiyun ^b   Carson, Richard E ^b   Hannestad, Jonas ^c   Cosgrove, Kelly P ^a,b   Fowler, Joanna S ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c UCB PHARMA   (Belgium)

^d BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Cytokines; Endotoxin; Microglia; Neuroinflammation; PBR28

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CARRIER PROTEIN; CYTOKINE; ENDOTOXIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MOLECULAR MARKER; PBR 28 C 11; TRACER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; ACETAMIDE DERIVATIVE; AUTACOID; BIOLOGICAL MARKER; CARBON; LIPOPOLYSACCHARIDE; N-(2-METHOXYBENZYL)-N-(4-PHENOXYPYRIDIN-3-YL)ACETAMIDE; PROTEIN BINDING; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TSPO PROTEIN, HUMAN;

ADULT; ARTICLE; BRAIN BLOOD VESSEL; BRAIN REGION; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; HUMAN EXPERIMENT; INNATE IMMUNITY; MALE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; UPREGULATION; VITAL SIGN; BLOOD; BRAIN; IMMUNOLOGY; METABOLISM; PROCEDURES; REPRODUCIBILITY; YOUNG ADULT;

ACETAMIDES; ADULT; BIOMARKERS; BRAIN; CARBON RADIOISOTOPES; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MALE; MICROGLIA; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTORS, GABA; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84943405909     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1511003112     Document Type: Article

References (63)

1. Kostic M, Stojanovic I, Marjanovic G., Zivkovic N, Cvetanovic A. (2015) Deleterious versus protective autoimmunity in multiple sclerosis. Cell Immunol 296(2):122-132.
2. Cameron B, Landreth G.E. (2010) Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis 37(3):503-509.
3. Hurley LL, Tizabi Y. (2013) Neuroinflammation, neurodegeneration, and depression. Neurotox Res 23(2):131-144.
4. Kelley KW, Dantzer R. (2011) Alcoholism and inflammation: Neuroimmunology of behavioral and mood disorders. Brain Behav Immun 25(Suppl 1):S13-S20.
5. Streit WJ, Mrak RE, Griffin W.S. (2004) Microglia and neuroinflammation: A pathological perspective. J Neuroinflammation 1(1):14.
6. Heneka MT, et al (2015) Neuroinflammation in Alzheimer's disease. Lancet Neurol 14(4):388-405.
7. Marchi N, Granata T, Janigro D. (2014) Inflammatory pathways of seizure disorders. Trends Neurosci 37(2):55-65.
8. Moehle MS, West A.B. (2015) M1 and M2 immune activation in Parkinson's Disease: Foe and ally? Neuroscience 302:59-73.
9. Aloisi F (2001) Immune function of microglia. Glia 36(2):165-179.
10. Carson MJ, et al (2007) A rose by any other name? The potential consequences of mi-croglial heterogeneity during CNS health and disease. Neurotherapeutics 4(4):571-579.
11. Kettenmann H, Kirchhoff F, Verkhratsky A. (2013) Microglia: New roles for the syn-aptic stripper. Neuron 77(1):10-18.
12. Dheen ST, Kaur C, Ling E.A. (2007) Microglial activation and its implications in the brain diseases. Curr Med Chem 14(11):1189-1197.
13. Zhao YN, et al (2013) Activated microglia are implicated in cognitive deficits, neuronal death, and successful recovery following intermittent ethanol exposure. Behav Brain Res 236(1):270-282.
14. Dantzer R, O'Connor JC, Freund GG, Johnson R.W., Kelley K.W. (2008) From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci 9(1):46-56.
15. Yirmiya R, Goshen I. (2011) Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 25(2):181-213.
16. Papadopoulos V, et al (2006) Translocator protein (18 kDa): New nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 27(8):402-409.
17. Doorduin J, de Vries EF, Dierckx RA, Klein H.C. (2008) PET imaging of the peripheral benzodiazepine receptor: Monitoring disease progression and therapy response in neurodegenerative disorders. Curr Pharm Des 14(31):3297-3315.
18. Fujita M, et al (2008) Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage 40(1):43-52.
19. Liu GJ, et al (2014) The 18 kDa translocator protein, microglia and neuroinflammation. Brain Pathol 24(6):631-653.
20. Venneti S, Lopresti BJ, Wiley C.A. (2006) The peripheral benzodiazepine receptor (Translocator protein 18 kDa) in microglia: From pathology to imaging. Prog Neurobiol 80(6):308-322.
21. Bae KR, Shim HJ, Balu D, Kim S.R., Yu S.W. (2014) Translocator protein 18 kDa negatively regulates inflammation in microglia. J Neuroimmune Pharmacol 9(3):424-437.
22. Kreisl WC, et al (2013) In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain 136(Pt 7):2228-2238.
23. Colasanti A, et al (2014) In vivo assessment of brain white matter inflammation in multiple sclerosis with (18)F-PBR111 PET. J Nucl Med 55(7):1112-1118.
24. 11C]PBR28 PET study. Brain Behav Immun 33:131-138.
25. Narendran R, et al (2014) Cocaine abuse in humans is not associated with increased microglial activation: An 18-kDa translocator protein positron emission tomography imaging study with [11C]PBR28. J Neurosci 34(30):9945-9950.
26. Park E, et al (2015) (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: Test-retest reproducibility and focal visualization of active white matter areas. Eur J Nucl Med Mol Imaging 42(7):1081-1092.
27. Setiawan E, et al (2015) Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 72(3): 268-275.
28. Tufekci KU, Genc S, Genc K. (2011) The endotoxin-induced neuroinflammation model of Parkinson's disease. Parkinsons Dis 2011:487450.
29. Mosser DM, Edwards J.P. (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8(12):958-969.
30. Nakagawa Y, Chiba K. (2014) Role of microglial m1/m2 polarization in relapse and remission of psychiatric disorders and diseases. Pharmaceuticals (Basel) 7(12):1028-1048.
31. Cunningham C (2013) Microglia and neurodegeneration: The role of systemic inflammation. Glia 61(1):71-90.
32. 11C]PBR28 positron emission tomography in nonhuman primates. Neuroimage 63(1): 232-239.
33. Schedlowski M, Engler H, Grigoleit J.S. (2014) Endotoxin-induced experimental systemic inflammation in humans: A model to disentangle immune-to-brain communication. Brain Behav Immun 35:1-8.
34. Owen DR, et al (2012) An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 32(1):1-5.
35. Kreisl WC, et al (2013) A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab 33(1):53-58.
36. Hannestad J, et al (2012) Glucose metabolism in the insula and cingulate is affected by systemic inflammation in humans. J Nucl Med 53(4):601-607.
37. Biswas SK, Lopez-Collazo E (2009) Endotoxin tolerance: New mechanisms, molecules and clinical significance. Trends Immunol 30(10):475-487.
38. Camara ML, et al (2015) Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. Neuropsychopharmacology 40(2):502-512.
39. Delpech JC, et al (2015) Transgenic increase in n-3/n-6 fatty acid ratio protects against cognitive deficits induced by an immune challenge through decrease of neuroinflammation. Neuropsychopharmacology 40(3):525-536.
40. Zheng X, et al (2014) Peripheral immunomodulation with ginsenoside Rg1 ameliorates neuroinflammation-induced behavioral deficits in rats. Neuroscience 256:210-222.
41. Biesmans S, et al (2013) Systemic immune activation leads to neuroinflammation and sickness behavior in mice. Mediators Inflamm 2013:271359.
42. Hannestad J, DellaGioia N, Ortiz N., Pittman B, Bhagwagar Z. (2011) Citalopram reduces endotoxin-induced fatigue. Brain Behav Immun 25(2):256-259.
43. Bromander S, et al (2012) Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: An observational study. J Neuroinflammation 9:242.
44. Owen DR, et al (2014) Determination of [(11)C]PBR28 binding potential in vivo: A first human TSPO blocking study. J Cereb Blood Flow Metab 34(6):989-994.
45. Fink MP (2014) Animal models of sepsis. Virulence 5(1):143-153.
46. Haudek SB, et al (2003) Lipopolysaccharide dose response in baboons. Shock 20(5): 431-436.
47. Orihuela R, McPherson CA, Harry G.J. (2015) Microglial M1/M2 polarization and metabolic states. Br J Pharmacol, in press.
48. Boche D, Perry VH, Nicoll J.A. (2013) Review: Activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol 39(1):3-18.
49. Kreutzberg GW (1996) Microglia: A sensor for pathological events in the CNS. Trends Neurosci 19(8):312-318.
50. Fischer R, Maier O. (2015) Interrelation of oxidative stress and inflammation in neurodegenerative disease: Role of TNF. Oxid Med Cell Longev 2015:610813.
51. Zotova E, et al (2011) Microglial alterations in human Alzheimer's disease following Aβ42 immunization. Neuropathol Appl Neurobiol 37(5):513-524.
52. Giunti D, Parodi B, Cordano C., Uccelli A, Kerlero de Rosbo N (2014) Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis. Immunology 141(3):328-339.
53. McGeer PL, McGeer E.G. (2015) Targeting microglia for the treatment of Alzheimer's disease. Expert Opin Ther Targets 19(4):497-506.
54. Condello C, Yuan P, Schain A., Grutzendler J. (2015) Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques. Nat Commun 6: 6176.
55. Li Y, Tan MS, Jiang T, Tan L. (2014) Microglia in Alzheimer's disease. Biomed Res Int 2014:437483.
56. Garrido-Mesa N., Zarzuelo A, Gálvez J (2013) Minocycline: Far beyond an antibiotic. Br J Pharmacol 169(2):337-352.
57. Yaghmoor F, et al (2014) The role of TREM2 in Alzheimer's disease and other neurological disorders. J Alzheimers Dis Parkinsonism 4(5):160.
58. Zanotti-Fregonara P., et al (2014) Synthesis and evaluation of translocator 18 kDa protein (TSPO) positron emission tomography (PET) radioligands with low binding sensitivity to human single nucleotide polymorphism rs6971. ACS Chem Neurosci 5(10):963-971.
59. Fan Z, et al (2015) Can studies of neuroinflammation in a TSPO genetic subgroup (HAB or MAB) be applied to the entire AD cohort? J Nucl Med 56(5):707-713.
60. Carson REBW, Liow J-S, Adler S, Johnson C.A. (2003) Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction of the HRRT. IEEE Nuclear Science Symposium and Medical Imaging Conference 5:3281-3285.
61. Gunn RN, Gunn SR, Cunningham V.J. (2001) Positron emission tomography compartmental models. J Cereb Blood Flow Metab 21(6):635-652.
62. Innis RB, et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27(9):1533-1539.
63. Ogden RT (2003) Estimation of kinetic parameters in graphical analysis of PET imaging data. Stat Med 22(22):3557-3568.